Pump and dump? Company will earn nearly $10/share this year. A multibillion dollar annual product just won approval today in Europe. The anemia and oncology franchises march on. What on earth are you bloviating about?
The Cometriq data appears to be a strong win in second-line kidney cancer. Not only is there a marked effect on PFS (a HR of 0.58 is very, very good for second-line therapy), but the drug prolonged overall survival for the first set of patients at a significance of P=0.005. This indicates it is extremely likely Cometriq will reach the overall survival secondary endpoint upon completion of the study by all participants.
The lack of serious adverse events with Cometriq is a big plus as well.